The United States recently secured 1.7 million doses of a compound that could help to treat Covid-19 patients. In preliminary studies, Molnupiravir reduced the transmission of the Sars-CoV-2 coronavirus. Researchers at the Max Planck Institute for Biophysical Chemistry in Göttingen and the Julius Maximilians University Würzburg have now elucidated the underlying molecular mechanism. The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus.
Molecular mechanisms of corona drug candidate Molnupiravir unraveled
August 16, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022